The Federal Government Is On The Brink
In today’s Journal, Porter explains the simple reason why this one sector of the market always outperforms the overall market and always will: these companies get all of their capital for free.
In today’s Journal, Porter explains the simple reason why this one sector of the market always outperforms the overall market and always will: these companies get all of their capital for free.
In today’s Journal, Porter explains the simple reason why this one sector of the market always outperforms the overall market and always will: these companies get all of their capital for free.
Our recommendation this month is a company on the vanguard of gene therapy, with several transformative medicines in its pipeline. Best of all, this company trades at a negative enterprise value, making it a compelling value – beyond its scientific promise.
For a variety of economic reasons, biotech has not participated in the current tech rally. And, as a result, there has likely never been a wider gap between tech stocks and biotech stocks. Right now, as we report in this week’s issue, a major biotech bull market is forming.
Today, Porter writes about Richard Russell, loved by investors for his market prognostications, but whose most insightful legacy is the surprisingly simple and timeless principles of successful investment that still stand the test of time.
Today Porter shares the details of his favorite presentation from last week’s conference and how readers should be sure not to miss this opportunity for 5x, even 10x gains in this sector.